Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Novacyt ( (FR:ALNOV) ) has provided an announcement.
Novacyt S.A. has announced a strategy update and an investor presentation detailing its growth plan and financial outlook for FY25. The company anticipates a slight increase in revenues for the second half of 2025, driven by new instrument sales, and expects improvements in EBITDA loss and cash outflow. Novacyt has set organic financial goals, including double-digit revenue growth starting FY26, maintaining a gross margin over 60%, and achieving EBITDA profitability. The company is focusing on restructuring and leveraging its core capabilities to meet emerging market needs, with investments to accelerate product launches and a mixed strategy of licensing and in-house product development.
More about Novacyt
Novacyt is an international molecular diagnostics company that offers a wide range of integrated technologies and services, focusing primarily on genomic medicine. The company develops, manufactures, and commercializes molecular assays and instrumentation to provide seamless end-to-end solutions across various sectors including human health, animal health, and environmental applications. Novacyt operates through three business segments: Clinical, Instrumentation, and Research Use Only, with a commercial presence in over 65 countries.
See more data about ALNOV stock on TipRanks’ Stock Analysis page.